TY - JOUR
T1 - Batimastat reduces Mycobacterium tuberculosis-induced apoptosis in macrophages
AU - Santucci, M. B.
AU - Ciaramella, A.
AU - Mattei, M.
AU - Sumerska, T.
AU - Fraziano, M.
PY - 2003/11
Y1 - 2003/11
N2 - In this study, we report evidences that Mycobacterium tuberculosis (MTB)-induced apoptosis in macrophages is reduced by a broad-spectrum hydroxamic acid-based matrix metalloproteinase (MMP) inhibitor, Batimastat (BB-94). In particular, we show that BB-94 administration to MTB-infected macrophages inhibits apoptosis and the downmodulation of membrane CD14 expression. Moreover, the addition of broad spectrum matrix metalloproteinase inhibitor to cell culture, during MTB infection, decreases the release of soluble TNF-α and leads to a simultaneous increase of membrane TNF-α. These results show that MTB-induced apoptosis in macrophages is reduced by a MMP inhibitor and most probably is related to TNF-α release. This identifies BB-94 as a simultaneous anti-apoptotic and anti-inflammatory molecule during MTB infection.
AB - In this study, we report evidences that Mycobacterium tuberculosis (MTB)-induced apoptosis in macrophages is reduced by a broad-spectrum hydroxamic acid-based matrix metalloproteinase (MMP) inhibitor, Batimastat (BB-94). In particular, we show that BB-94 administration to MTB-infected macrophages inhibits apoptosis and the downmodulation of membrane CD14 expression. Moreover, the addition of broad spectrum matrix metalloproteinase inhibitor to cell culture, during MTB infection, decreases the release of soluble TNF-α and leads to a simultaneous increase of membrane TNF-α. These results show that MTB-induced apoptosis in macrophages is reduced by a MMP inhibitor and most probably is related to TNF-α release. This identifies BB-94 as a simultaneous anti-apoptotic and anti-inflammatory molecule during MTB infection.
KW - Apoptosis
KW - Metalloproteinases
KW - Monocytes/macrophages
KW - MTB infection
KW - TNF-α
UR - http://www.scopus.com/inward/record.url?scp=0141861004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0141861004&partnerID=8YFLogxK
U2 - 10.1016/S1567-5769(03)00202-9
DO - 10.1016/S1567-5769(03)00202-9
M3 - Article
C2 - 14555290
AN - SCOPUS:0141861004
VL - 3
SP - 1657
EP - 1665
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
IS - 12
ER -